NxStage Medical Inc. (NASDAQ:NXTM)’s share price rose 5.7% during trading on Tuesday . The company traded as high as $25.49 and last traded at $25.42, with a volume of 581,822 shares. The stock had previously closed at $24.05.

NXTM has been the topic of a number of recent research reports. BTIG Research restated a “buy” rating and set a $27.00 price objective on shares of NxStage Medical in a research note on Tuesday, June 7th. Piper Jaffray Cos. restated a “buy” rating and set a $21.00 price objective on shares of NxStage Medical in a research note on Friday, June 3rd. Zacks Investment Research upgraded NxStage Medical from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research note on Wednesday, July 6th. Canaccord Genuity restated a “buy” rating on shares of NxStage Medical in a research note on Wednesday, May 4th. Finally, Jefferies Group raised their price objective on NxStage Medical from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Friday. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. NxStage Medical currently has an average rating of “Buy” and a consensus target price of $26.43.

The firm has a 50 day moving average price of $21.81 and a 200 day moving average price of $18.02. The stock’s market cap is $1.63 billion.

NxStage Medical (NASDAQ:NXTM) last posted its quarterly earnings data on Thursday, August 4th. The medical device company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.01. The firm earned $92.20 million during the quarter, compared to analysts’ expectations of $89.44 million. NxStage Medical’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.08) EPS. Equities research analysts forecast that NxStage Medical Inc. will post ($0.12) earnings per share for the current fiscal year.

In related news, President Joseph E. Turk, Jr. sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, May 12th. The stock was sold at an average price of $17.89, for a total value of $26,835.00. Following the transaction, the president now owns 103,280 shares in the company, valued at $1,847,679.20. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Several large investors recently bought and sold shares of NXTM. Jennison Associates LLC increased its stake in NxStage Medical by 32.9% in the fourth quarter. Jennison Associates LLC now owns 1,395,174 shares of the medical device company’s stock valued at $30,568,000 after buying an additional 345,394 shares in the last quarter. Trexquant Investment LP increased its stake in NxStage Medical by 142.4% in the fourth quarter. Trexquant Investment LP now owns 57,700 shares of the medical device company’s stock valued at $1,264,000 after buying an additional 33,900 shares in the last quarter. Wells Fargo & Company MN increased its stake in NxStage Medical by 6.5% in the fourth quarter. Wells Fargo & Company MN now owns 1,450,307 shares of the medical device company’s stock valued at $31,777,000 after buying an additional 88,286 shares in the last quarter. Morgan Stanley increased its stake in NxStage Medical by 1.3% in the fourth quarter. Morgan Stanley now owns 67,174 shares of the medical device company’s stock valued at $1,472,000 after buying an additional 874 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in NxStage Medical by 4.1% in the fourth quarter. New York State Common Retirement Fund now owns 76,493 shares of the medical device company’s stock valued at $1,676,000 after buying an additional 3,000 shares in the last quarter.

NxStage Medical, Inc is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.